Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash from Investing Activities (2016 - 2025)

Cytosorbents' Cash from Investing Activities history spans 15 years, with the latest figure at -$291000.0 for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$291000.0 for Q4 2025, down 134.68% from a year ago — trailing twelve months through Dec 2025 was -$415000.0 (up 37.97% YoY), and the annual figure for FY2025 was -$415000.0, up 37.97%.
  • Cash from Investing Activities for Q4 2025 was -$291000.0 at Cytosorbents, down from $55000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $140285.0 in Q2 2023 to a low of -$4.7 million in Q2 2022.
  • The 5-year median for Cash from Investing Activities is -$274357.5 (2023), against an average of -$637853.6.
  • The sharpest move saw Cash from Investing Activities plummeted 528.53% in 2021, then surged 118.39% in 2025.
  • Year by year, Cash from Investing Activities stood at -$1.7 million in 2021, then skyrocketed by 87.68% to -$206080.0 in 2022, then soared by 34.04% to -$135922.0 in 2023, then rose by 8.77% to -$124000.0 in 2024, then plummeted by 134.68% to -$291000.0 in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$291000.0, $55000.0, and -$131758.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.